This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping us understand which sections of the website you find most interesting and useful. See our Cookie Policy for more information.
These cookies are used to deliver our website and content. Strictly necessary cookies relate to our hosting environment, and functional cookies are used to facilitate social logins, social sharing and rich-media content embeds.
Enables storage (such as cookies) related to analytics e.g. visit duration.
Enables storage related to personalization e.g. video recommendations
Enables storage (such as cookies) related to advertising.
Pharma & Biotech
Sustainability
Cannabis
Battery Metals
Artificial Intelligence
Emily began her career as a political journalist for Australian Community Media in Hobart, Tasmania. After she relocated to Toronto, Canada, she reported on business, legal, and scientific developments in the emerging psychedelics sector before joining Proactive in 2022. She brings a strong journalism background with her work featured in newspapers, magazines, and digital publications across Australia, Europe, and North America, including The Examiner, The Advocate, The Canberra Times, and… Read more
Proactive financial news and online broadcast teams provide fast, accessible, informative and actionable business and finance news content to a global investment audience. All our content is produced independently by our experienced and qualified teams of news journalists.
Proactive news team spans the world’s key finance and investing hubs with bureaus and studios in London, New York, Toronto, Vancouver, Sydney and Perth.
We are experts in medium and small-cap markets, we also keep our community up to date with blue-chip companies, commodities and broader investment stories. This is content that excites and engages motivated private investors.
The team delivers news and unique insights across the market including but not confined to: biotech and pharma, mining and natural resources, battery metals, oil and gas, crypto and emerging digital and EV technologies.
Proactive has always been a forward looking and enthusiastic technology adopter.
Our human content creators are equipped with many decades of valuable expertise and experience. The team also has access to and use technologies to assist and enhance workflows.
Proactive will on occasion use automation and software tools, including generative AI. Nevertheless, all content published by Proactive is edited and authored by humans, in line with best practice in regard to content production and search engine optimisation.
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You understand that the Content on the Site is provided for information purposes only, and none of the information contained on the Site constitutes an offer, solicitation or recommendation to buy or sell a security. You understand that the Company receives either monetary or securities compensation for our services. We stand to benefit from any volume which any Content on the Site may generate. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, suitability or profitability of any particular security, portfolio of securities, transaction, investment, investment strategy, or other matter. You understand…
In exchange for publishing services rendered by the Company on behalf of atai Life Sciences named herein, including the promotion by the Company of atai Life Sciences in any Content on the Site, the Company receives from said issuer annual cash compensation of typically up to $25,000.
Published: 16:21 15 Apr 2024 EDT
atai Life Sciences (NASDAQ:ATAI, ETR:9VC) made significant strides in advancing its innovative mental health therapies in 2023, with a focus on psychedelic-based treatments for depression.
CEO and co-founder Florian Brand joined Proactive to discuss the company’s recent milestones including encouraging clinical trial results, what to expect from its ongoing research programs and upcoming catalysts for both the company and the broader psychedelics sector.
Proactive: In 2023, there was a big focus on psychedelic-based therapies for depression. Take us through some of the milestones you achieved.
FB: 2023 was a year where we remained highly committed to developing very differentiated and novel innovative mental health therapies. The team made a tremendous amount of progress with our own program as well as some of the new programs we onboarded.
Earlier in January, we announced the strategic investment in Beckley Psytech which has two depression programs in development, BLP-003 and ELE-101. Both are psychedelic and seem to fit into that two-hour treatment window that was successfully established by Spravato (ketamine) that has been approved in 2019 by the FDA and has been proven to be effective in depression. We want to leverage the infrastructure that J&J put out with Spravato with BLP-003 and ELE-101 as well as our own DMT program which is called VLS-01.
There are a lot of good things happening in the depression space at atai. While we are also exploring some other indications, the short-duration psychedelics were indeed a core focus for us over the last month.
You’ve just announced some results from a Phase 2 trial of BLP-003. Are you encouraged by what you’re seeing?
Absolutely. It was a Phase 2, open-label trial in treatment-resistant depression. Treatment-resistant depression affects roughly a third of the depression population, so there’s more than 100 million people suffering from that type of depression where they don’t respond to available treatment options. What we’ve seen here with BLP-003, which is a 5-MeO-DMT program, is rapid-acting relief from depression and durable antidepressant effects. 45% of the patients were in remission at month three after a single dose.
If you look at depression and how it’s been historically treated, there are many SSRI antidepressants approved for at-home use, which you take chronically at home. Here, we’re looking at a therapy that after a single administration, one dose, achieved really durable effects after about three months. That’s very encouraging. As we were just talking about Spravato, what we’ve also seen here is that the acute effects of BLP-003 are resolved within an average of less than two hours, which is encouraging because it increases our conviction that it could fit into the in-clinic treatment paradigm that was successfully established by Spravato.
Where do you take the BLP-003 program from here?
We reported data from part one. There’s a part two that will look at co-administration of BPL-003 with SSRIs or antidepressants. Then, importantly, we have a large Phase 2b study going in 225 treatment-resistant depression patients. We anticipate results in the second half of this year and that will be a very exciting catalyst for the entire space of depression research and also for us at atai of course.
Touch on some of the other programs you are looking at.
In the depression space, we touched on BLP-003 or ELE-101 fitting into that two-hour window – we also want our proprietary oral transmucosal DMT formulation to fit into that two-hour in-clinic treatment paradigm that was established by Spravato. Here we also hope to achieve rapid and durable antidepressant effects.
It’s pharmacologically different from BPL-003, which is 5-MeO-DMT. So even if it’s called DMT, it’s quite different from 5-MeO-DMT pharmacologically, for example, from a receptor binding perspective. If we assume it to be also clinically differentiated, we could add another tool in the psychiatrists’ toolbox.
You mentioned the Phase 2b BLP-003 program results, what other catalysts are you expecting in 2024?
Another very important one is the COMP360 Phase 3 trial readout [from Compass Pathways (NASDAQ:CMPS), in which atai has a more than 20% stake] which is guided for Q4. It is one of the most advanced trials in the psychedelic research space and is important for the overall neuropsychiatry space to see those results, and, of course, also very exciting for atai.
In addition to all the programs we discussed area, we have a very interesting and important Phase 2b trial going on in cognitive impairment associated with schizophrenia (CIS). We are testing RL-007, which is a pro-cognitive neuromodulator. It is a non-psychedelic program. We are testing this compound in the schizophrenia patient population and hope to see significant cognitive improvement in that population. It’s often very prevalent in schizophrenia patients. We anticipate having data for this trial mid-next-year.
Quotes have been edited for clarity and style
Sign up to receive alerts and news direct to your inbox
atai Life Sciences (NASDAQ:ATAI, ETR:9VC) co-founder and CEO Florian Brand takes Proactive's Stephen Gunnion through the significant advancements the company made in 2023 in developing innovative mental health therapies, particularly focusing on psychedelic-based treatments for…
Copyright © Proactive Group Holdings Inc, 2024
All Rights Reserved – Proactive North America Inc., Proactive Investors LLC.
Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use.
atai Life Sciences CEO spotlights psychedelic therapy milestones and upcoming catalysts – Proactive Investors USA
